CONTEMPORARY HEALTH SYSTEMS Announces the USPTO has issued a Patent for its
Biomarker Assessment of Olfactory and Gustatory Functioning for Detection and
Monitoring of multiple neurological diseases and downstream medical conditions

WEST PALM BEACH, Fla—Contemporary Health Systems, LLC, a life sciences developer of
predictive, early biomarker assessments of cognitive and sensory functioning, announced that it
has received a U. S. Patent for its non-invasive assessment of olfactory and gustatory functioning,
which has valid proof of concept multiple uses as a diagnostic screener, longitudinal assessment
tool and treatment outcomes indicator.

NEURO-Scan™ features a proprietary 5-minute assessment of the four sensory components
identified physiologically as the ‘four corners’ of taste and smell. Loss or diminished taste and
smell was identified early by the Centers of Disease Control(CDC) as a recognized early
symptom of Sars-Cov2(corona virus), which extends the importance of the assessment of these
sensory deficits beyond the multiple other medical and neurological conditions already known to
be marked by these sensory deficits. It is easy to administer in the office or at home, validly
detects impairments and improvements in function, and normative standards for performance
are available.

The NEURO-Scan assessment is indicated for the detection and assessment of sensory
changes in multiple cognitive and neurological conditions including ordnance- atmospheric- and
kinetic-induced concussion, Long COVID, Alzheimer’s Disease, Parkinson’s Disease, dementia,
ALS, Repetitive Head Injury(RHI), chronic traumatic encephalopathy(CTE), post-traumatic
stress disorder(PTSD) and traumatic brain injury(TBI). Extensive proof of concept peer-reviewed research data validation supports the assessment of olfactory and gustatory functioning as an early indicator and improvement tracker of these conditions. This test-of-function biomarker assessment is recommended to all healthcare providers for their patients for early/periodic evaluations and screenings.

Dr. Philip Harvey, Leonard M. Miller Professor of Psychiatry at the University of Miami Miller
School of Medicine said that “The importance of assessing these sensory deficits for the
identification and management of multiple medical and neurological conditions is clear. In contrast to other assessment strategies, which examine diagnostic biomarkers that do not change with improvement, olfactory and gustatory functions can change with improvements in clinical condition and have wide-ranging promise as an early diagnostic biomarker as well as an indicator of clinical improvement.”

An easily administered test of function assessment of olfactory and gustatory biomarkers has the potential for very broad use in medical and neurological assessments, including repeated
assessments without the practice or exposure effects associated with performance-based cognitive assessments or biases associated self-reports of functioning.

About Contemporary Health Systems
Contemporary Health System, LLC is a predictive Life Sciences company engaged in the research of test-of-function, first in-class assessments to address unmet clinical needs. NEURO- Scan™ is
new, novel, unrivaled and is destined to become an integral part of “The Acceptable Standard of Care” for all HealthCare Providers.

"NEURO-Scan" and "CovaKit" are registered trademarks of Contemporary Health Systems, LLC and are FDA Registered Class 2 Medical Devices with 510K exemptions.

Contact:
Dr. Robert Fish
Chief Science Officer, Director
dr.robertfish@contemporaryhs.com